IPM Take
This is not a claim that HIFU is the answer for every prostate cancer patient. It is a story about access to choice. Prostate cancer treatment is not only survival. It is urinary function, sexual function, fear of recurrence, travel, trust and whether a patient can actually reach the option that fits his disease and priorities. For veterans, that access question sits inside a federal system that can either reduce inequality or reproduce it.
Executive Summary
FocalTherics announced an agreement with MellingMedical to expand access to Focal One Robotic HIFU for federal healthcare providers, including VA and Department of Defense healthcare systems. The company said nearly 500,000 veterans are receiving prostate cancer treatment or care within the Veterans Healthcare System, and that veterans are diagnosed with prostate cancer at twice the rate of the general population. Through MellingMedical’s VA Federal Supply Schedule, federal healthcare facilities can acquire Focal One Robotic HIFU, adding an incision-free and radiation-free focal therapy option to the treatment landscape.
Why it matters
- Veterans: Access to prostate cancer options should include quality of life, not only tumour control.
- Urologists: Focal therapy requires careful patient selection, counselling and follow-up.
- Federal providers: Procurement channels can shape whether innovation reaches public systems or stays concentrated in private centres.
- Public payers: Function-preserving technologies need evidence, appropriate use and equitable deployment.
Prostate cancer treatment is often presented as a menu of clinical options. In real life, not every patient gets the menu.
Some options are available only in certain centres. Some require referral. Some depend on technology procurement. Some patients are told what is locally available rather than what might fit their disease, function and preferences.
That is why the FocalTherics-MellingMedical agreement is worth watching. It is not only about a device. It is about whether federal systems can widen access to prostate cancer technologies that may offer selected patients a less invasive route than surgery or radiation.
The key word is selected. HIFU is not automatically right for every prostate cancer patient. It requires appropriate staging, imaging, risk assessment, physician expertise and long-term follow-up. It should be framed as an additional option, not a universal replacement.
The veteran angle makes this more than a medtech story. FocalTherics says veterans are diagnosed with prostate cancer at twice the rate of the general population and that nearly 500,000 are receiving treatment or care within the Veterans Healthcare System. That gives procurement decisions real weight. If a technology enters the VA and DoD pathway, it can affect access across a large public system.
For IPM, this is a useful access story because it expands the discussion beyond drugs. Personalised cancer care is also about matching intervention intensity to patient goals, disease risk and quality of life. Innovation matters only when patients can reach it, understand it and choose it appropriately.
